A federal consultative group voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is not final. The FDA has given no indication on whether it will move in step with the panel. The move came after weeks of public hearings. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could alter how the agency handles a part of the wellness market that is surging ahead. Market observers are watching to see if the agency takes up the plan. A representative for the regulator offered no set date for a response. Industry voices argue the change would widen access to compounds people say help them. Opponents warn that looser rules could weaken safeguards across a wide-open market. The advisory vote only sets up a possible shift, and the final say rests with the regulator.